Sartorius Stedim Biotech (CHIX:DIMP) Net Income (Continuing Operations): €294 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DIMP Sartorius Stedim Biotech SA CHIX:DIMP
83 GF Score
Price €191.10
GF Value €202.02
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Net Income (Continuing Operations)?

Sartorius Stedim Biotech CHIX:DIMP 83 Net Income (Continuing Operations) is €294 Mil as of Jun. 2026. GuruFocus rates CHIX:DIMP with a GF Score™ of 83/100 and a GF Value™ of €202.02 (Fairly Valued). The stock has 6 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Sartorius Stedim Biotech's Net Income (Continuing Operations) for the three months ended in Jun. 2026 was €94 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was €294 Mil.

Sartorius Stedim Biotech  (CHIX:DIMp) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Sartorius Stedim Biotech Net Income (Continuing Operations) Related Terms

Sartorius Stedim Biotech Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Sartorius Stedim Biotech's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech Net Income (Continuing Operations) Chart

Sartorius Stedim Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 414.30 879.90 312.70 178.50 265.90

Sartorius Stedim Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.60 64.80 47.30 88.10 93.80
CHIX:DIMP
83GF Score
Sartorius Stedim Biotech SA CHIX:DIMP
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius Stedim Biotech Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €294 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of €294 Mil mean?
Sartorius Stedim Biotech (CHIX:DIMP) has a Net Income (Continuing Operations) of €294 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Sartorius Stedim Biotech and its competitors.
Is Sartorius Stedim Biotech's Net Income (Continuing Operations) too high?
Sartorius Stedim Biotech's current Net Income (Continuing Operations) is €294 Mil. Overall, Sartorius Stedim Biotech has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Net Income (Continuing Operations) compare to ISRG and BDX?
Sartorius Stedim Biotech's Net Income (Continuing Operations) of €294 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Medical Devices & Instruments company?
A good Net Income (Continuing Operations) depends on the Medical Devices & Instruments industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current Net Income (Continuing Operations) is €294 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Fairly Valued. The stock's GF Value™ is €202.02, compared to a current price of €191.10 — trading 5.4% below its estimated fair value. The current Net Income (Continuing Operations) is €294 Mil. Sartorius Stedim Biotech's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Net Income (Continuing Operations) is €294 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €191.10 is trading 5.4% below its estimated GF Value™ of €202.02. GuruFocus considers Sartorius Stedim Biotech to be Fairly Valued.

Key valuation signals for CHIX:DIMP:

  • Net Income (Continuing Operations): €294 Mil
  • GF Value™: €202.02 vs. price of €191.10 (5.4% below fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
83GF Score

Get the complete analysis for CHIX:DIMP

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€191.10
Price
€202.02
GF Value